Darifenacin or darifenacin hydrobromide

A cell-permeable inhibitor of sirtuin NAD+-dependent deacetylases, inhibiting the yeast sirtuin Sir2p with an IC50 value of 68 &muM and the human sirtuins SIRT1 and SIRT2 with IC50 values of 131 and 38 &muM, respectively does not alter HDAC1

InformationSitravatinib (MGCD516, MG-516) is a novel small molecule inhibitor targeting multipleRTKsinvolved in driving sarcoma cell growth, including c-Kit, PDGFRβ, PDGFRα, c-Met, and Axl.In vitroMGCD516 (Sitravatinib), is an oral, potent small

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including MSDS and any product information leaflets have been developed and issued under the Authority of the

General description This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under

InformationSR-4370 is a potent and selective inhibitor of class I HDACs with IC50 of 0.13 µM, 0.58 µM, 0.006 µM, 2.3 µM, 3.7 µM forHDAC 1,HDAC 2,HDAC 3,HDAC 8,HDAC 6, respectively.SR-4370 suppresses AR signaling and in vivo prostate tumor

InformationSR-4370 is a potent and selective inhibitor of class I HDACs with IC50 of 0.13 µM, 0.58 µM, 0.006 µM, 2.3 µM, 3.7 µM forHDAC 1,HDAC 2,HDAC 3,HDAC 8,HDAC 6, respectively.SR-4370 suppresses AR signaling and in vivo prostate tumor

InformationSR-4370 is a potent and selective inhibitor of class I HDACs with IC50 of 0.13 µM, 0.58 µM, 0.006 µM, 2.3 µM, 3.7 µM forHDAC 1,HDAC 2,HDAC 3,HDAC 8,HDAC 6, respectively.SR-4370 suppresses AR signaling and in vivo prostate tumor

InformationSR-4370 is a potent and selective inhibitor of class I HDACs with IC50 of 0.13 µM, 0.58 µM, 0.006 µM, 2.3 µM, 3.7 µM forHDAC 1,HDAC 2,HDAC 3,HDAC 8,HDAC 6, respectively.SR-4370 suppresses AR signaling and in vivo prostate tumor

InformationTalazoparib (BMN 673, LT-673) is a novelPARPinhibitor withIC50of 0.57 nM for PARP1 in a cell-free assay. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 3.In vitroBMN-673

A cell-permeable dihydrothiopyranopyrimidinol that binds TNKS1/PARP5a and TNKS2/PARP5b with high affinity (K d = 99 and 93 nM, respectively) and potently inhibits their PARsylation (poly ADP-ribosylation) activity (IC 50 = 11 and 4 nM,